Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Alexandre Larouze; Mario Alcocer-Ávila; Clément Morgat; Christophe Champion; Elif Hindié

doi:10.2967/jnumed.123.265509

Research ArticleBasic Science Investigation

Membrane and Nuclear Absorbed Doses from ¹⁷⁷Lu and ¹⁶¹Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, Christophe Champion and Elif Hindié

Journal of Nuclear Medicine October 2023, 64 (10) 1619-1624; DOI: https://doi.org/10.2967/jnumed.123.265509

Alexandre Larouze

1Université de Bordeaux–CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, Talence, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mario Alcocer-Ávila

1Université de Bordeaux–CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, Talence, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Clément Morgat

2Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christophe Champion

1Université de Bordeaux–CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, Talence, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elif Hindié

2Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France; and

3Institut Universitaire de France, Paris, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 64 no. 10 1619-1624

DOI

https://doi.org/10.2967/jnumed.123.265509

PubMed

37321819

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication January 25, 2023
Revision received May 11, 2023
Published online October 3, 2023.

Article Versions

previous version (June 15, 2023 - 08:30).
You are viewing the most recent version of this article.

Author Information

Alexandre Larouze¹,
Mario Alcocer-Ávila¹,
Clément Morgat²,
Christophe Champion¹ and
Elif Hindié²,³

¹Université de Bordeaux–CNRS-CEA, Centre Lasers Intenses et Applications, UMR 5107, Talence, France;
²Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, UMR CNRS 5287, INCIA, Talence, France; and
³Institut Universitaire de France, Paris, France

For correspondence or reprints, contact Elif Hindié (elif.hindie{at}chu-bordeaux.fr) or Christophe Champion (christophe.champion{at}u-bordeaux.fr).

View Full Text

Statistics from Altmetric.com

Cited By...

13 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics

Cristina Müller, Nicholas P. van der Meulen, Roger Schibli

European Journal of Nuclear Medicine and Molecular Imaging 2023 50 11
Advances in Radioligand Theranostics in Oncology

Ismaheel O. Lawal, Sofiullah O. Abubakar, Honest Ndlovu, Kgomotso M. G. Mokoala, Stuart S. More, Mike M. Sathekge

Molecular Diagnosis & Therapy 2024 28 3
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Hong Song, Maria Isabel Leonio, Valentina Ferri, Heying Duan, Carina Mari Aparici, Guido Davidzon, Benjamin L. Franc, Farshad Moradi, Jagruti Shah, Colin P. Bergstrom, Alice C. Fan, Sumit Shah, Ali Raza Khaki, Sandy Srinivas, Andrei Iagaru

European Journal of Nuclear Medicine and Molecular Imaging 2024 51 9
Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

C. Morgat, M. Van de Voorde, S. Bodin, C. Champion, E. Hindié

Médecine Nucléaire 2023 47 6
Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases

Laura De Nardo, Sara Santi, Anna Dalla Pietà, Guillermina Ferro-Flores, Erika Azorín-Vega, Emma Nascimbene, Vito Barbieri, Alessandra Zorz, Antonio Rosato, Laura Meléndez-Alafort

EJNMMI Physics 2024 11 1
Physics and small‐scale dosimetry of α$\alpha$‐emitters for targeted radionuclide therapy: The case of 211At$^{211}{\rm At}$

Mario Enrique Alcocer‐Ávila, Alexandre Larouze, Jean‐Emmanuel Groetz, Elif Hindié, Christophe Champion

Medical Physics 2024 51 7
Cytotoxicity Comparison of 99mTc-Labeled Peptide Antagonist and Agonist Targeting the SSTR2 Receptor in AR42J Cells

Sahar Nosrati Shanjani, Monika Łyczko, Rafał Walczak, Przemysław Koźmiński, Emilia Majka, Jerzy Narbutt, Wioletta Wojdowska, Agnieszka Majkowska-Pilip, Aleksander Bilewicz

Molecules 2025 30 8
Extracellular vesicles role in radio(nuclide)therapy

J Constanzo, J-P Pouget

Journal of Radiation Research 2024 65 Supplement_1
Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine

Clément Morgat, Andrei Iagaru, Elif Hindié

Journal of Nuclear Medicine 2025 66 2
Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161

Joana F. Santos, Camille Van Laere, Catarina D. Silva, Irwin Cassells, Célia Fernandes, Paula Raposinho, Ana Belchior, Catarina I. G. Pinto, Filipa Mendes, Christopher Cawthorne, Maarten Ooms, Michiel Van de Voorde, Frederik Cleeren, António Paulo

EJNMMI Radiopharmacy and Chemistry 2025 10 1

Article usage

Article usage: June 2023 to April 2025

	Abstract	Full	Pdf
Jun 2023	1786	90	49
Jul 2023	431	15	7
Aug 2023	233	4	7
Sep 2023	165	18	8
Oct 2023	655	82	39
Nov 2023	152	157	34
Dec 2023	59	68	16
Jan 2024	87	152	37
Feb 2024	38	225	22
Mar 2024	34	141	28
Apr 2024	24	225	26
May 2024	35	96	24
Jun 2024	34	87	20
Jul 2024	17	149	31
Aug 2024	13	120	22
Sep 2024	27	62	30
Oct 2024	25	80	34
Nov 2024	38	121	53
Dec 2024	20	76	35
Jan 2025	27	75	37
Feb 2025	37	171	42
Mar 2025	25	140	55
Apr 2025	25	84	34

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 10

October 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Membrane and Nuclear Absorbed Doses from ¹⁷⁷Lu and ¹⁶¹Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, Christophe Champion, Elif Hindié

Journal of Nuclear Medicine Oct 2023, 64 (10) 1619-1624; DOI: 10.2967/jnumed.123.265509

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Membrane and Nuclear Absorbed Doses from ¹⁷⁷Lu and ¹⁶¹Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, Christophe Champion, Elif Hindié

Journal of Nuclear Medicine Oct 2023, 64 (10) 1619-1624; DOI: 10.2967/jnumed.123.265509

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions
Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine

Google Scholar

Keywords

targeted radionuclide therapy
177Lu
161Tb
terbium-161
absorbed dose

Main menu

User menu

Search

Membrane and Nuclear Absorbed Doses from ¹⁷⁷Lu and ¹⁶¹Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Article Information

Article Versions

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: June 2023 to April 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords